SCHEMBL10183787

SCHEMBL10183787

C=C/C(=C(\C)F)N(C(=O)Cc1cccs1)C1C(=O)N(C2CCCCC2)c2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 1/20 0.37
▸ OPRM1 P35372 4/20 0.36
▸ OPRK1 P41145 4/20 0.36
▸ OPRL1 P41146 3/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.35
▸ MCHR1 Q99705 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.33
▸ GAA P10253 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ HPGD P15428 1/20 0.32
▸ TRPM8 Q7Z2W7 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ OPRD1 P41143 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10183947 0.99 SIGMAR1 (0.38) SIGMAR1OPRM1OPRK1OPRL1NPSR1
SCHEMBL10183656 0.87 SIGMAR1 (0.39) SIGMAR1OPRM1OPRK1OPRL1NPSR1
SCHEMBL10184045 0.78 OPRM1 (0.42) SIGMAR1OPRM1OPRK1OPRL1NPSR1
SCHEMBL10185637 0.77 SIGMAR1 (0.37) SIGMAR1NPSR1ALDH1A1GAAMEN1
SCHEMBL10184154 0.75 POLB (0.39) SIGMAR1OPRM1OPRK1OPRL1NPSR1
SCHEMBL10183666 0.75 OPRM1 (0.39) SIGMAR1OPRM1OPRK1OPRL1NPSR1
SCHEMBL10185945 0.75 OPRM1 (0.39) SIGMAR1OPRM1OPRK1OPRL1NPSR1
SCHEMBL10185926 0.75 OPRM1 (0.39) SIGMAR1OPRM1OPRK1OPRL1NPSR1
SCHEMBL10183670 0.74 TRPM8 (0.41) SIGMAR1OPRM1OPRK1OPRL1NPSR1
SCHEMBL10184153 0.73 OPRM1 (0.39) SIGMAR1OPRM1OPRK1OPRL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012009678-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE AGIOS PHARMACEUTICALS, INC. (US) 2012-01-19 — — WO disclosed
Send feedback